医学
德诺苏马布
前列腺癌
唑来膦酸
骨质疏松症
不利影响
内科学
雄激素剥夺疗法
肿瘤科
泌尿科
癌症
作者
Aaron P. Mitchell,David Nemirovsky,Akriti Mishra Meza,Nirjhar Chakraborty,Sonia Persaud,Azeez Farooki,Michael J. Morris
出处
期刊：JCO oncology practice
[American Society of Clinical Oncology]
日期：2024-01-08
卷期号：20 (3): 393-400
被引量：1
摘要
Bone-modifying agents (BMAs) do not prevent skeletal-related events among patients with castration-sensitive prostate cancer (CSPC), but many patients receive BMAs unnecessarily. The costs to Medicare from overuse have not been assessed.
科研通智能强力驱动
Strongly Powered by AbleSci AI
cocolu
爱静静
Polymer72
带头大哥
VDC
QDU
mhl11
子车茗
tuanheqi
乐乐乐乐乐乐
pluto
劲秉
嗯哼
HEIKU
hhhblabla
Jack80
Candice
萧水白
luoshi
一一
皖公网安备34019202002308
